Positron emission tomography in uro-oncology

Area of Science:

• Nuclear medicine and molecular imaging
• Uro-oncology
• Diagnostic imaging techniques

Background:

• Positron emission tomography (PET) development in uro-oncology has been slow due to tracer excretion issues.
• PET's utility in prostate cancer is limited, often failing to distinguish malignancy from benign prostatic hypertrophy.
• Challenges exist in differentiating recurrent disease from fibrosis in the treatment bed using conventional CT/MR imaging.

Purpose of the Study:

• To review the current and potential applications of PET in uro-oncology.
• To evaluate PET's effectiveness in staging, recurrence detection, and treatment response assessment for various urologic cancers.
• To highlight the impact of new tracers and ongoing research in advancing PET's role.

Main Methods:

• Review of existing literature on PET applications in prostate, testicular, renal, and bladder cancers.
• Analysis of PET's diagnostic performance compared to conventional imaging modalities.
• Discussion of technical challenges and future directions for PET in uro-oncology.

Main Results:

• PET shows limited success in early prostate cancer but is valuable for detecting recurrence in advanced disease.
• PET is effective in testicular cancer for defining recurrent disease in residual masses and in patients with elevated markers.
• PET may serve as an adjunct in renal and bladder cancers for difficult cases and local staging, and for differentiating post-treatment fibrosis from recurrence.

Conclusions:

• PET has a defined role in specific uro-oncology scenarios, particularly in advanced disease and testicular cancer.
• Further research and development of novel tracers are essential to expand PET's utility in uro-oncology.
• PET offers potential benefits in challenging diagnostic situations and for assessing treatment outcomes across urologic malignancies.